INHIBITION OF FOCAL ADHESION KINASE FOR CONTROL OF SCAR TISSUE FORMATION

• US 20130165463A1
• Filed: 12/05/2012
• Published: 06/27/2013
• Est. Priority Date: 12/09/2011
• Status: Active Grant

• Current Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.)
• Original Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.)
• Inventors: Gurtner, Geoffrey C., Longaker, Michael T., Wong, Victor W.
• Granted Patent: US 9,655,967 B2
• Time in Patent Office: Days
• US Class Current: 514/275
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The formation of scars at a wound site is reduced by contacting the wound site with an effective dose of an inhibitor of focal adhesion kinase (FAK) activity or expression. Blockade of FAK is sufficient to prevent mechanical and inflammatory stimuli from activating MCP-1 pathways. In addition to these chemokine-mediated mechanisms, inhibition of FAK may control fibrosis by blocking fibroblast collagen production. Pharmacologic blockade of FAK significantly reduces scar formation in vivo.

Claims

1. A method of reducing scarring during healing of a skin wound, comprising:

administering a pharmaceutical formulation comprising an effective dose of an FAK inhibitor to a subject with a skin wound, for a period of time sufficient to reduce scarring as compared to a healed wound of an untreated subject.

2. The method of claim 1, wherein said FAK inhibitor is administered systemically to the subject.

3. The method of claim 2, wherein the administration is intradermal injection or microneedle injection.

4. The method of claim 1, wherein said FAK inhibitor is administered topically to the skin wound.

5. The method of claim 4, wherein the inhibitor is administered in a topical solution or lotion.

6. The method of claim 4, wherein the inhibitor is administered as a patch in a wound dressing.

7. The method of claim 4, wherein the FAK inhibitor is administered as a solution for wound irrigation.

8. The method of claim 1, wherein said pharmaceutical formulation further comprises one or both of an antibiotic and a non-steroidal anti-inflammatory drug.

9. The method of claim 1, wherein the FAK inhibitor is administered for a period of at least 3 days.

10. The method of claim 1, wherein the FAK inhibitor is administered for a period of at least one week.

11. The method of claim 1, wherein said scarring is hypertrophic scaring.

12. The method of claim 1, further comprising debridement or removal of pre-existing scar tissue

13. The method of claim 1, wherein the subject is a human.

14. The method of claim 1, wherein the gross scar area is reduced by at least about 25% relative to an untreated subject.

15. The method of claim 1, wherein the gross scar area is reduced by about 100% relative to an untreated subject.

16. A wound dressing for use in the methods of claim 6, wherein said wound dressing comprises an effective dose of an FAK inhibitor.

17. The method of claim 16, wherein the FAK inhibitor is comprised in a patch.

18. The method of claim 16, wherein the FAK inhibitor is provided in a sustained release depot.

19. A kit for use in the methods set forth in claim 1, comprising a pharmaceutical formulation of an FAK inhibitor.

20. The kit of claim 19, wherein the pharmaceutical formulation is for topical or intradermal use.